Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Publications

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: Final results of a phase 2, single-blind, randomised controlled trial (COV006).

Li G. et al, (2025), Vaccine, 62

Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: results from COV-BOOST trial.

Janani L. et al, (2025), J Infect

Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in Brazil

Costa Clemens SA. et al, (2025), Mayo Clinic Proceedings Innovations Quality and Outcomes, 9

Precision Data Management: Using REDCap and Large Language Models to Optimise Clinical Trial Efficiency

Mujadidi YF. et al, (2025)

Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009): A prospective cohort study.

Feng S. et al, (2025), J Infect, 90

Safety and broad immunogenicity of HIVconsvX conserved mosaic candidate T-cell vaccines vectored by ChAdOx1 and MVA in HIV-CORE 006: a double-blind, randomised, placebo-controlled phase 1 trial in healthy adults living without HIV-1 in eastern and southern Africa

Chanda C. et al, (2025), The Lancet Microbe

Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a randomised controlled trial.

Conlin K. et al, (2024), Vaccine, 45

5-year vaccine protection following a single dose of Vi-tetanus toxoid conjugate vaccine in Bangladeshi children (TyVOID): a cluster randomised trial.

Qadri F. et al, (2024), Lancet, 404, 1419 - 1429

Modelling Salmonella Typhi in high-density urban Blantyre neighbourhood, Malawi, using point pattern methods.

Khaki JJ. et al, (2024), Sci Rep, 14

Pathogen diversity and antimicrobial resistance transmission of Salmonella enterica serovars Typhi and Paratyphi A in Bangladesh, Nepal, and Malawi: a genomic epidemiological study.

Dyson ZA. et al, (2024), Lancet Microbe

Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study.

Jackson S. et al, (2024), Lancet Microbe, 5, 655 - 668

Immune responses to typhoid conjugate vaccine in a two dose schedule among Nepalese children <2 years of age.

Bijukchhe SM. et al, (2024), Vaccine, 42, 2018 - 2025

Intravenous immunoglobulin treatment in childhood encephalitis (IgNiTE): a randomised controlled trial.

Hill M. et al, (2023), BMJ Open, 13

Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial.

Kelly E. et al, (2023), J Infect, 87, 230 - 241

Direct inference and control of genetic population structure from RNA sequencing data.

Fachrul M. et al, (2023), Commun Biol, 6

Optimising DTwP-containing vaccine infant immunisation schedules (OptImms) - a protocol for two parallel, open-label, randomised controlled trials.

Kelly S. et al, (2023), Trials, 24

Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.

Liu X. et al, (2023), J Infect, 87, 18 - 26

Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.

Shaw RH. et al, (2023), J Infect, 86, 574 - 583

Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511].

Liu X. et al, (2023), J Infect, 86, 540 - 541

Immune responses in children after vaccination with a typhoid Vi-tetanus toxoid conjugate vaccine in Bangladesh.

Khanam F. et al, (2023), Vaccine

Load More